SCHEMBL3520731

SCHEMBL3520731

O=C(O)c1c(O)c(Br)cc2ncc(-c3ccccc3)nc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
AKR1C4 P17516 1/20 0.41
AKR1C3 P42330 1/20 0.41
AKR1C2 P52895 1/20 0.41
AKR1C1 Q04828 1/20 0.41
PDGFRB P09619 1/20 0.41
KDR P35968 1/20 0.41
FLT3 P36888 1/20 0.41
DHODH Q02127 2/20 0.40
PDE10A Q9Y233 2/20 0.40
TLR9 Q9NR96 1/20 0.40
BCHE P06276 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3524091 0.89 DHODH (0.40) NPC1RAB9ADHODHKMT2A
SCHEMBL3520359 0.85 EGLN3 (0.44) SMN1; SMN2NPC1RAB9APDGFRBKDR
SCHEMBL3519670 0.84 KMO (0.44) DHODHALDH1A1GAA
SCHEMBL3519681 0.84 EGLN3 (0.54) ALDH1A1
SCHEMBL3532730 0.82 DHODH (0.47) SMN1; SMN2DHODHGLAKDM4EKMT2A
SCHEMBL3537332 0.78 KMO (0.45) DHODHALDH1A1HPGDKDM4ELMNA
SCHEMBL3761475 0.78 NPC1 (0.45) NPC1RAB9AALDH1A1HPGDLMNA
SCHEMBL3527577 0.78 TLR9 (0.43) SMN1; SMN2NPC1RAB9APDGFRBKDR
SCHEMBL3518631 0.76 SMN1; SMN2 (0.45) SMN1; SMN2NPC1RAB9APDGFRBKDR
SCHEMBL3518064 0.75 SMN1; SMN2 (0.42) SMN1; SMN2NPC1RAB9APDGFRBKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 SMN1; SMN2 3777/4885NPC1 2674/4885RAB9A 3111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.